# Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial

Supplementary Material

S.Figure 1: Treatment plan

Abbreviations: AUC, area under the concentration-time curve; BC, breast cancer; Car, carboplatin; FISH, fluorescence in situ hybridization; H, trastuzumab; IHC, immunohistochemistry; P, paclitaxel.

S.Figure 2: Left ventricular ejection fraction (LVEF) per treatment arm.

Central horizontal lines show medians, limits of shaded boxes show 50th percentile, horizontal lines outside

S.Table 1: Odds ratios for pathological complete response according to subgroups

	Category	Univariable		Mutivarible	
		Odds ratio (95% CI)	*P* value	Odds ratio (95% CI)	*P* value
Arm	PCH vs PEH	1.481 (0.632-3.472)	0.365	3.606 (1.153-11.274)	0.027
Age	<45y vs ≥45y	1.218 (0.504-2.945)	0.662	1.053 (0.338-3.279)	0.930
cT	cT1-2 vs cT3-4	0.490 (0.19q-1.258)	0.135	0.407 (0.134-1.232)	0.112
cN	Negative vs positive	0.721 (0.212-2.447)	0.599	0.332 (0.054-2.057)	0.236
Ki67	<14% vs ≥14%	1.737 (0.479-6.295)	0.397	2.483 (0.407-15.153)	0.324
HR status	Negative vs positive	0.607 (0.259-1.426)	0.251	0.550 (0.177-1.711)	0.302
Chemotherapy cycles	4 cycles vs 5-6 cycles	1.364 (0.583-3.190)	0.474	2.671 (0.881-8.794)	0.106
FCGR2A	H/H vs H/R and R/R	0.561 (0.224-1.406)	0.216	0.330 (0.098-1.110)	0.073
FCGR3A	F/F vs F/V and V/V	1.294 (0.521-3.214)	0.578	1.348 (0.432-4.209)	0.607
PIK3CA	Wid type vs mutated	0.799 (0.316-2.024)	0.637	0.799 (0.250-2.550)	0.705
TP53	Wid type vs mutated	1.404 (0.558-3.533)	0.471	0.813 (0.235-2.808)	0.743
PTEN	Normal vs Loss	1.103 (0.378-3.219)	0.857	0.694 (0.159-3.024)	0.627

S.Table 2: Cardiac and most common adverse events reported as possibly, probably, or definitely related to treatment

Adverse event	HPC group (N=50)		HPE goup (N=50)	
	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4
Anemia	30	7	33	5
Febrile neutropenia	0	4	0	7
Neutropenia	17	28	12	35
Leucopenia	14	4	15	13
Thrombocytopenia	10	3	5	1
Granulocytopenia	22	23	20	26
ALP increased	3	0	1	0
Bilirubin increased	26	1	23	2
AST increased	16	1	13	0
ALT increased	22	4	22	0
Hand-foot syndrome	3	0	9	0
Diarrhea	8	1	6	1
Nausea	29	0	31	0
Vomiting	23	0	21	0
Fatigue	24	0	22	1
Peripheral neuropathy	6	0	7	0
Arthralgia/myalgia	0	0	0	0
Congestive heart failure	0	0	0	0
Palpitation	4	0	5	0
Lung infection	1	1	1	1